What Anaveon does

Anaveon AG is a Swiss clinical-stage biotechnology company headquartered at Tech Park Basel (Hochbergerstrasse 60C, CH-4057 Basel), founded in 2018 to develop engineered antibodies and cytokine-based fusion proteins that selectively eliminate or reprogram pathogenic immune cells. The company's therapeutic premise is that immune-mediated diseases arise from dysregulation of upstream regulatory nodes, and that targeting those nodes — rather than individual downstream mediators — can restore durable immune balance without broadly suppressing immune function.

The pipeline rests on a proprietary PD-1-targeted cytokine platform that uses non-blocking PD-1 epitopes to enable proximity-activated 'cis-signaling' delivery of cytokines to tumor-reactive or pathogenic T cells. The lead immunology asset, ANV200, is a precision-engineered PD-1-depleting antibody in preclinical development for autoimmune and inflammatory diseases, with clinical testing planned in the near future. The legacy oncology portfolio comprises ANV600 (sunekafusp alpha), a first-in-class PD-1-targeted IL-2R-βγ agonist currently in Phase 1 with clinical benefit data presented at ASCO 2026 (42% disease control as monotherapy, 59% with pembrolizumab, including a CR in a CPI-resistant NSCLC patient); ANV700, a preclinical PD-1-targeted IL-21 fusion protein; and ANV419, an earlier-generation IL-2 fusion from prior clinical work.

Anaveon is pre-revenue and operates an enterprise partnering model. The company is actively seeking global development and commercialization partners for its oncology portfolio (ANV600, ANV700) via license, co-development, or acquisition structures, while advancing its core immunology pipeline internally toward clinical development. To date, Anaveon has raised approximately CHF 110 million in a December 2021 Series B led by Forbion with participation from Syncona, Novartis Venture Fund, Cowen Healthcare Investments, Pfizer Ventures, and Pontifax. Investors also include Blue Owl. The company has 11–50 employees and in 2026 underwent a comprehensive leadership overhaul — appointing Thaminda Ramanayake (CEO), Eric Zanelli (CSO), Jill Jene (CBO), and Thomas P. Mathers (Chairman) — alongside a strategic pivot emphasizing immunology over pure oncology.

Name

Anaveon

Legal name

Anaveon AG

Website

https://anaveon.com

Company type

Private

Founded year

2018

Operating status

Operating

Headcount range

11–50 employees

Short description

Anaveon AG is a Swiss preclinical-stage biotechnology company developing engineered antibodies and cytokine-based fusion proteins that selectively eliminate or reprogram pathogenic immune cells for autoimmune and oncology indications. It seeks global pharmaceutical partners for its oncology portfolio while advancing lead immunology asset ANV200 toward the clinic.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

Dendritic Cell & Other APC-based Therapies (HLAAABAF)

akta.pro secondary industries

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ), Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD), Personalized Therapeutic Design (neoantigen vaccines, individualized cell/gene therapies) (HLAAANAK), Immunoglobulins & Passive Immunization Biologics (IVIG, hyperimmune globulins, antitoxins) (HLAAAEAH)

Keywords

• Engineered antibodies
• Cytokine therapeutics
• Immuno-oncology biologics
• Autoimmune disease therapies
• Precision biologics

Headquarters

HQ city

Bottmingen

HQ country

Switzerland

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

1. Pipeline Development and Licensing: Pre-revenue preclinical biotech company. Primary value creation through advancing proprietary immunology pipeline (ANV200, ANV600, ANV700) toward clinical milestones, with intent to partner or out-license oncology assets. Revenue model will depend on eventual clinical and commercial partnerships, licensing deals, or co-development arrangements.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels5 records

Core offering

Anaveon develops precision-engineered antibodies and cytokine-based fusion proteins that act on upstream regulatory nodes of the immune system to selectively eliminate or reprogram pathogenic immune cells. Its lead immunology asset, ANV200, is a precision-engineered antibody designed for deep depletion of PD-1-expressing pathogenic T cells in autoimmune diseases, while its legacy oncology portfolio (ANV600, ANV700, ANV419) is being advanced through clinical and preclinical development and is open to global pharmaceutical partnering, licensing, co-development, or acquisition.

Product overview

Anaveon is developing a portfolio of engineered antibodies and cytokine-based therapies designed to selectively eliminate or reprogram pathogenic immune cells. The core pipeline includes ANV200 (preclinical, lead immunology asset for autoimmune diseases), while the legacy oncology portfolio includes ANV600 (Phase 1 IL-2R-βγ agonist), ANV700 (preclinical IL-21 fusion), and ANV419 (earlier generation IL-2 fusion). The company is seeking partners for its oncology assets while prioritizing its immunology pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

• ANV200 ANV200 is a precision-engineered antibody designed for deep depletion of the full spectrum of PD-1-expressing pathogenic T cells that drive harmful immune responses in autoimmune diseases. It acts on a key upstream control point of the immune system to reset pathogenic immune responses and restore tissue homeostasis, and is intended to influence multiple downstream disease mechanisms. The asset is currently in preclinical development, with clinical testing planned in the near future. It is being advanced as Anaveon's lead immunology asset.
• ANV600 (sunekafusp alpha) ANV600 (sunekafusp alpha) is a first-in-class, non-blocking PD-1-targeted IL-2R-βγ agonist designed to selectively expand tumor-reactive PD-1+ CD8+ effector T cells while reducing toxicities historically associated with IL-2 therapy. It binds PD-1 on a unique non-blocking epitope distinct from checkpoint inhibitors and aims to activate tumor antigen-experienced T cells within the tumor microenvironment, with potential in checkpoint-refractory tumors and in combination with checkpoint inhibitors. The asset is in Phase 1 clinical development (EXPAND-1) and is part of the legacy oncology portfolio Anaveon is actively seeking to partner.
• ANV419 ANV419 is an earlier-generation IL-2/anti-IL-2 fusion protein (not PD-1-targeted) with demonstrated safety in prior clinical studies. It is positioned as part of Anaveon's legacy oncology portfolio alongside ANV600 and ANV700, and is included in the oncology assets the company is actively seeking to partner, license, co-develop, or divest.

Quantifiable outcome

• Disease control (CR, PR, or SD) observed in 42% of patients treated with ANV600 monotherapy and 59% of patients receiving ANV600 plus pembrolizumab
• +5 more outcomes

Named customers1 record

Segments1 record

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

One partnership is on record.

• BioNTechminorStrategic or Co-development PartnerThaminda Ramanayake, now CEO of Anaveon, played a key role in CureVac's transformation and its acquisition by BioNTech in 2025. This represents a historical personal connection rather than a direct company-to-company partnership.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Medicenna Therapeutics: Clinical-stage immuno-oncology company developing engineered IL-2/IL-4 Superkines and PD-1-IL-2 fusion proteins (MDNA11) — directly comparable mechanism and indication overlap with Anaveon's ANV600 and proximity-activated cytokine strategy.
• Werewolf Therapeutics: Clinical-stage biotech using its PREDATOR/INDUKINE platforms to engineer tumor-selective, conditionally activated cytokine therapeutics — directly parallel to Anaveon's PD-1-targeted cytokine engineering approach.
• NeoImmuneTech / Genexine: Developer of long-acting IL-7 (NT-I7/efineptakin alfa) and other cytokine-based immunotherapies — comparable cytokine engineering focus with overlapping oncology and immunology applications.
• Bicycle Therapeutics: Clinical-stage biotech developing bicyclic peptide-based precision oncology therapeutics including immune cell engagers — comparable engineered biologic platform philosophy targeting tumor-selective immune activation.
• Adagene: Clinical-stage biotech using AI-driven antibody engineering to develop precision immuno-oncology biologics, including PD-1-targeting candidates — comparable precision biologic approach with similar tumor-selective antibody engineering philosophy.
• Cullinan Oncology: Multi-asset clinical-stage oncology company developing precision immunotherapies with similar partnered-program development model and platform-extension mindset.

Emerging players

• Hookipa Pharma: Clinical-stage biotech developing arenavirus-based immunotherapies to induce potent T cell responses against oncology targets — overlapping immunotherapy focus with comparable precision immune-activation approach.
• Compugen: Clinical-stage computational immunology company developing antibody-based therapeutics for cancer immunotherapy — comparable precision biologics development with computational discovery angle.

Broad incumbents

• Eli Lilly: Major pharmaceutical company with a leading immunology/autoimmune franchise (Taltz, Olumiant) and active acquirer in the space — relevant as a potential strategic acquirer/partner and as the incumbent benchmark in autoimmune precision biologics.
• Sanofi: Major pharmaceutical company with significant autoimmune and immunology franchise (Dupixent) and a venture arm that has historically backed cytokine engineering platforms — relevant both as a potential acquirer and as an incumbent benchmark.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/anaveon-ag

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds2 records

Investors6 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Anaveon